[custom_adv]
South Korean drugmaker Samsung Biologics (207940.KS) plans to add a mRNA vaccine production line at its facility in Songdo, 30 kilometres southwest of Seoul, by the first half of 2022. Messenger RNA (mRNA) vaccines are known for their safety and fast scalability in manufacturing, the company said in a statement on Monday, and have been among the first COVID-19 vaccines authorised for use in the United States.
